Viking Therapeutics Inc Stock

Viking Therapeutics (NASDAQ: VKTX) has emerged as a beacon of hope in an otherwise lackluster year for healthcare stocks. The buzz around its mid-stage weight loss candidate, VK2735, has propelled

Viking Therapeutics (NASDAQ: VKTX) has been flying on all cylinders since the beginning of the year. The company's shares are up 246% due to excellent clinical progress. It's not rare for smaller

Does a 100% return in less than seven years sound pretty good? Most investors would probably say so. But which stocks are good candidates to achieve such a gain?

Three Motley Fool contributors think

CRISPR Therapeutics (NASDAQ: CRSP) and Viking Therapeutics (NASDAQ: VKTX) are among the hottest mid-cap biotechs on the market. Both have delivered incredible progress in recent months, be it on the

Viking Therapeutics (NASDAQ: VKTX) has shown its strengths from a potential product perspective and an investment perspective in recent times. The company reported excellent data from clinical

One of the hottest areas of the pharmaceutical industry right now is the weight loss treatment space. Novo Nordisk and Eli Lilly have been the primary innovators. Their groundbreaking glucagon-like

Madrigal Pharmaceuticals (NASDAQ: MDGL) and Viking Therapeutics (NASDAQ: VKTX) are both biotechs developing treatments for metabolic diseases, so it's to be expected that they have more than a few

Are we witnessing the rise of a new biotech giant? A few weeks ago, Viking Therapeutics (NASDAQ: VKTX) grabbed headlines when it reported positive results from a phase 2 clinical trial for VK2735, a

Viking Therapeutics (NASDAQ: VKTX) is on a tear this year, with shares catapulting upward by 340% thanks to good data (and high expectations) from one of its mid-stage clinical trials testing a

What's the most important ingredient for investing successfully? Time. However, some stocks require much less time to deliver huge returns than others.

You may have to be patient for significant

Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) have seen their revenue soar in recent times thanks to their weight loss drugs. The companies sell products that target key hormones involved in

There aren't many hotter stocks on the market right now than Viking Therapeutics (NASDAQ: VKTX). Shares of the biopharmaceutical company have skyrocketed around 340% so far this year.

However, those

Investors looking for stocks that can make dramatic gains in a short time frame might want to turn their attention to the biopharmaceutical industry. Shares of Viking Therapeutics (NASDAQ: VKTX)

One of the biggest tailwinds in the pharmaceutical industry is weight loss treatments. Breakthroughs in semaglutide and tirzepatide have given rise to several glucagon-like peptide-1 (GLP-1)

2024 is off to a great start for many investors, with the S&P 500 climbing 10.2% in the first quarter, roughly the performance the index averages for an entire year. Since the end of 2022, the S&P

Viking Therapeutics (NASDAQ: VKTX) has emerged this year as a formidable contender in the increasingly popular anti-obesity market. While it doesn't have an approved drug fighting for market share

Relatively small biotechs can see their shares soar -- sometimes significantly -- following positive clinical or regulatory news.

That's what has happened this year to Viking Therapeutics (NASDAQ:

Investors are very eager to buy into biotechs and pharmaceuticals that are involved in developing weight-loss medications. This is why Viking Therapeutics (NASDAQ: VKTX), which has such a drug in

What's the hottest biotech stock on the market right now? If we limit the list only to those with market caps of at least $500 million, it's Viking Therapeutics (NASDAQ: VKTX). So far in 2024

Shares of Viking Therapeutics (NASDAQ: VKTX) had skyrocketed by 25% as of 11:08 a.m. ET on Tuesday. That big gain came after the company announced results from a phase 1 clinical study evaluating an

When it comes to rising stars in biotech, Viking Therapeutics (NASDAQ: VKTX) should probably be one of the first businesses to come to mind today. The company doesn't yet have any sales revenue, but

Some investors might remember the obesity drugs developed by Arena Pharmaceuticals and Vivus Pharmaceuticals several years ago. They'll probably also recall that the initial euphoria over those

There's no shortage of hype and excitement surrounding Viking Therapeutics (NASDAQ: VKTX) stock these days. The company has a promising weight loss drug candidate in its pipeline at a time when many